BNTC HealthcareBeta data

Benitec Biopharma Inc.

$8.40-1.06%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 293.0M USD
Enterprise value: 113.8M USD
Full-time employees: 24

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Benitec Biopharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Benitec Biopharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
Benitec Biopharma has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

—Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.7%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-44.9%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.7%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield61.2%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity
▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.27

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.06Sector median: 0.6250 · MAD: 0.3380

Current ratio34.00×

Yahoo FinanceOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo FinanceReported value33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Benitec Biopharma

Is Benitec Biopharma getting weaker?: Its latest SEC filing (Sep 14, 2026) showed no major changes.
How is Benitec Biopharma valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.7% vs peers 1.5% (weaker than 100% of peers).
Is Benitec Biopharma growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Benitec Biopharma?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Benitec Biopharma?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 34.00× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 34.00× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Sep 14, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−41.5M USD	−45.5M USD	+9.6%
Free cash flow (12 months)	−19.8M USD	−16.6M USD	−16.1%
Cash	184.8M USD	180.0M USD	−2.6%
Shares outstanding	34.4M	34.9M	+1.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Jun 2022	FY Jun 2023	FY Jun 2024	FY Jun 2025	FY Jun 2026	Change
Operating margin	-24457.5%	-25441.3%	—	—	—	—
Net margin	-24942.5%	-26082.7%	—	—	—	—
Return on assets (ROA)	-304.8%	-438.2%	-41.7%	-38.1%	-24.9%	▲ 13 pts
Return on equity (ROE)	-631.8%	-9684.2%	-46.0%	-39.0%	-25.7%	▲ 13 pts
Free cash flow margin	-21797.3%	-24017.3%	—	—	—	—
Current ratio	1.90×	0.94×	10.49×	54.67×	34.00×	▼ 38%

BNTC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Benitec Biopharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Benitec Biopharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

Benitec Biopharma has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about Benitec Biopharma

Is Benitec Biopharma getting weaker?

Its latest SEC filing (Sep 14, 2026) showed no major changes.

How is Benitec Biopharma valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.7% vs peers 1.5% (weaker than 100% of peers).

Is Benitec Biopharma growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Benitec Biopharma?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Benitec Biopharma?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 34.00× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 34.00× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−41.5M USD

−45.5M USD

+9.6%

Free cash flow (12 months)

−19.8M USD

−16.6M USD

−16.1%

Cash

184.8M USD

180.0M USD

−2.6%

Shares outstanding

34.4M

34.9M

+1.5%

Key ratios

FY Jun 2022

FY Jun 2023

FY Jun 2024

FY Jun 2025

FY Jun 2026

Change

Operating margin

-24457.5%

-25441.3%

—

Net margin

-24942.5%

-26082.7%

—

Return on assets (ROA)

-304.8%

-438.2%

-41.7%

-38.1%

-24.9%

▲ 13 pts

Return on equity (ROE)

-631.8%

-9684.2%

-46.0%

-39.0%

-25.7%

▲ 13 pts

Free cash flow margin

-21797.3%

-24017.3%

—

Current ratio

1.90×

0.94×

10.49×

54.67×

34.00×

▼ 38%